Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period

Several virus-neutralizing monoclonal antibodies (mAbs) have become new tools in the treatment of the coronavirus disease (COVID-19), but their effectiveness against the rapidly mutating virus is questionable. The present study investigated the effectiveness of Tixagevimab/Cilgavimab and Regdanvimab...

Descripción completa

Detalles Bibliográficos
Autores principales: Fomina, Daria S., Lebedkina, Marina S., Iliukhina, Anna A., Kovyrshina, Anna V., Shelkov, Artem Y., Andreev, Sergey S., Chernov, Anton A., Dolzhikova, Inna V., Kruglova, Tatyana S., Andrenova, Gerelma V., Tukhvatulin, Amir I., Shcheblyakov, Dmitry V., Karaulov, Alexander V., Lysenko, Maryana A., Logunov, Denis Y., Gintsburg, Alexander L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623550/
https://www.ncbi.nlm.nih.gov/pubmed/37928549
http://dx.doi.org/10.3389/fimmu.2023.1259725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623550/
https://www.ncbi.nlm.nih.gov/pubmed/37928549
http://dx.doi.org/10.3389/fimmu.2023.1259725

Ejemplares similares